Compare Stocks: AEON, ANVS, EXOZ, and TIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.23 -4.5%	$0.26	$0.18 ▼ $1.45	$11.57M	0.69	2.87 million shs	240,540 shs
ANVS Annovis Bio	$1.01 -4.2%	$1.41	$0.99 ▼ $5.50	$44.81M	1.23	774,420 shs	641,422 shs
EXOZ eXoZymes	$4.09 +2.3%	$6.13	$3.70 ▼ $18.40	$37.22M	3.19	9,021 shs	32,093 shs
TIL Instil Bio	$5.91 -3.6%	$7.23	$5.67 ▼ $20.33	$41.57M	1.94	23,034 shs	25,172 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	+6.16%	-21.61%	-8.51%	-17.60%	-77.91%
ANVS Annovis Bio	+3.12%	-9.27%	-6.04%	-39.22%	-41.76%
EXOZ eXoZymes	-13.14%	-28.33%	-39.12%	-29.66%	-68.68%
TIL Instil Bio	+3.03%	-6.55%	-14.98%	-17.39%	-70.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.23 -4.5%	$0.26	$0.18 ▼ $1.45	$11.57M	0.69	2.87 million shs	240,540 shs
ANVS Annovis Bio	$1.01 -4.2%	$1.41	$0.99 ▼ $5.50	$44.81M	1.23	774,420 shs	641,422 shs
EXOZ eXoZymes	$4.09 +2.3%	$6.13	$3.70 ▼ $18.40	$37.22M	3.19	9,021 shs	32,093 shs
TIL Instil Bio	$5.91 -3.6%	$7.23	$5.67 ▼ $20.33	$41.57M	1.94	23,034 shs	25,172 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	+6.16%	-21.61%	-8.51%	-17.60%	-77.91%
ANVS Annovis Bio	+3.12%	-9.27%	-6.04%	-39.22%	-41.76%
EXOZ eXoZymes	-13.14%	-28.33%	-39.12%	-29.66%	-68.68%
TIL Instil Bio	+3.03%	-6.55%	-14.98%	-17.39%	-70.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.75	Moderate Buy	$1.67	618.39% Upside
ANVS Annovis Bio	2.25	Hold	$12.00	1,092.84% Upside
EXOZ eXoZymes	1.50	Reduce	N/A	N/A
TIL Instil Bio	1.67	Reduce	$7.00	18.44% Upside

Current Analyst Ratings Breakdown

Latest AEON, ANVS, EXOZ, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	EXOZ eXoZymes	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/1/2026	AEON AEON Biopharma	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1.00 ➝ $2.00
9/9/2026	AEON AEON Biopharma	Laidlaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$1.80
9/2/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$8.00 ➝ $7.00
8/26/2026	EXOZ eXoZymes	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/19/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/14/2026	AEON AEON Biopharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$5.00 ➝ $1.20
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
EXOZ eXoZymes	$70K	543.39	N/A	N/A	$0.40 per share	10.23
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	1.29	N/A	N/A	N/A	N/A	-994.63%	11/13/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
EXOZ eXoZymes	-$9.16M	-$1.19	N/A	N/A	N/A	N/A	-292.15%	-158.66%	N/A
TIL Instil Bio	-$71.37M	-$4.47	N/A	N/A	N/A	N/A	-26.78%	-14.89%	11/16/2026 (Estimated)

Latest AEON, ANVS, EXOZ, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	N/A	AEON AEON Biopharma	-$0.10	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	ANVS Annovis Bio	-$0.30	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/13/2026	Q2 2026	EXOZ eXoZymes	N/A	-$0.33	N/A	-$0.33	N/A	N/A
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
ANVS Annovis Bio	N/A	3.47	3.47
EXOZ eXoZymes	0.01	3.81	3.81
TIL Instil Bio	0.79	21.67	21.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
ANVS Annovis Bio	15.83%
EXOZ eXoZymes	N/A
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	9.40%
ANVS Annovis Bio	15.92%
EXOZ eXoZymes	58.00%
TIL Instil Bio	47.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	8	49.88 million	74.37 million	Not Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
EXOZ eXoZymes	32	9.30 million	3.91 million	N/A
TIL Instil Bio	410	6.78 million	3.59 million	No Data

AEON, ANVS, EXOZ, and TIL Headlines

Recent News About These Companies

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26, 2026 | zacks.com

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

July 16, 2026 | seekingalpha.com

Instil Bio Shareholders Back Directors and Auditor at Meeting

June 11, 2026 | tipranks.com

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Instil Bio (TIL) Price Target Increased by 24.53% to 67.32

April 9, 2026 | msn.com

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 12, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 3, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,

January 27, 2026 | bakersfield.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 22, 2026 | prnewswire.com

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

January 20, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 20, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 15, 2026 | prnewswire.com

Instil Bio (TIL) Price Target Decreased by 45.17% to 53.55

January 14, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 8, 2026 | prnewswire.com

HC Wainwright & Co. downgrades Instil Bio (TIL)

January 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, ANVS, EXOZ, and TIL Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.23 -0.01 (-4.53%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 +0.00 (+2.16%)

As of 07:30 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Annovis Bio NYSE:ANVS

$1.01 -0.04 (-4.19%)

Closing price 03:59 PM Eastern

Extended Trading

$1.03 +0.02 (+2.29%)

As of 07:30 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

eXoZymes NASDAQ:EXOZ

$4.09 +0.09 (+2.25%)

Closing price 03:59 PM Eastern

Extended Trading

$4.20 +0.12 (+2.81%)

As of 07:30 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Instil Bio NASDAQ:TIL

$5.91 -0.22 (-3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$5.95 +0.04 (+0.74%)

As of 07:30 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEON, ANVS, EXOZ, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEON, ANVS, EXOZ, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEON, ANVS, EXOZ, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, ANVS, EXOZ, and TIL Company Descriptions

AEON Biopharma NASDAQ:AEON

Annovis Bio NYSE:ANVS

eXoZymes NASDAQ:EXOZ

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEON, ANVS, EXOZ, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEON, ANVS, EXOZ, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEON, ANVS, EXOZ, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, ANVS, EXOZ, and TIL Company Descriptions

AEON Biopharma NASDAQ:AEON

Annovis Bio NYSE:ANVS

eXoZymes NASDAQ:EXOZ

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools